标题 |
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
与常规治疗相比,SGLT2抑制剂、GLP-1受体激动剂和非甾体MRA联合治疗对2型糖尿病和蛋白尿患者终生心血管、肾脏和死亡率的益处估计
|
网址 | |
DOI | |
求助人 | |
下载 |